Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR)

enthalten in: Transplant Infectious Disease | 2023

von Doss, K. | Kling, C. | Heldman, M. | +5

Maribavir versus investigator assigned therapy : Exploring the exploratory

enthalten in: Transplant Infectious Disease | 2023

von Heldman, M. | Limaye, A.

Combined assessment of Epstein–Barr virus viral capsid antigen and Epstein–Barr virus nuclear antigen‐1 serology for post‐transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients

enthalten in: Transplant Infectious Disease | 2022

von Heldman, M. | Edlefsen, K. | Pepper, G. | +4

Treatment of multidrug‐resistant gram‐negative bacilli after solid organ transplant : Outcomes and complications

enthalten in: Transplant Infectious Disease | 2021

von Heldman, M. | Guo, K. | Nelson, B. | +2

Immunosuppression in solid organ transplant recipients with Covid‐19 : More data, but still complicated

enthalten in: Transplant Infectious Disease | 2021

von Heldman, M. | Kates, O. | Fisher, C. | +1

Pre‐ and post‐transplant bacterial infections in liver transplant recipients

enthalten in: Transplant Infectious Disease | 2019

von Heldman, M. | Ngo, S. | Dorschner, P. | +2